Breath and skin patch tests for early spread of melanoma
Tests breath and skin patch devices to detect early melanoma spread in adults.
Plain-language title generated from the registry record
Registry title: Precision Medicine for L/GCMN and Melanoma 2
Key facts
- Where
- Barcelona, SpainSee the 2 sites
Where in Spain
- Hospital Clinic BarcelonaBarcelona, SpainTaking people
- Hospital Clínic de Barcelona (Dermatology service)Barcelona, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundacion Clinic per a la Recerca Biomédica
- Trial code
- NCT06605443
- Record updated
- 27 February 2025
- Original description
The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients.Read full original descriptionShow less
Precision Medicine for L/GCMN and Melanoma 1 (Precis-mel 2)
The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients.
Inclusion: Be over 18 years old; Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC).
Exclusion: Present other cancers or chronic diseases (such as diabetes, asthma, etc.), which may affect the volatile organic compound profiles; Not signing the informed consent form.